A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer. [ESTUDIO DE FASE 2, ALEATORIZADO Y ABIERTO DE FIGITUMUMAB (CP-751,871) MÁS CISPLATINO (O CARBOPLATINO) Y ETOPOSIDO, FRENTE A CISPLATINO (O CARBOPLATINO) Y ETOPOSIDO SOLOS, COMO TRATAMIENTO DE PRIMERA LÍNEA EN PACIENTES CON CÁNCER DE PULMÓN MICROCÍTICO EN ESTADIO EXTENDIDO]

Trial Profile

A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer. [ESTUDIO DE FASE 2, ALEATORIZADO Y ABIERTO DE FIGITUMUMAB (CP-751,871) MÁS CISPLATINO (O CARBOPLATINO) Y ETOPOSIDO, FRENTE A CISPLATINO (O CARBOPLATINO) Y ETOPOSIDO SOLOS, COMO TRATAMIENTO DE PRIMERA LÍNEA EN PACIENTES CON CÁNCER DE PULMÓN MICROCÍTICO EN ESTADIO EXTENDIDO]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2013

At a glance

  • Drugs Figitumumab (Primary) ; Carboplatin; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Mar 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top